Statement: More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 8/56 (14.29%)   Platelets * 1/56 (1.79%)   Heart failure * 1/56 (1.79%)   Left ventricular systolic dysfunction * 1/56 (1.79%)   Dehydration * 1/56 (1.79%)   Diarrhea * 1/56 (1.79%)   Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%)   Sodium, serum-low (hyponatremia) * 1/56 (1.79%)   Fracture * 2/56 (3.57%)
Secondary_evidence: Adverse Events 1:   Total: 18/70 (25.71%)   Cardiac arrest  1/70 (1.43%)   Pericardial effusion  1/70 (1.43%)   Ear pain  1/70 (1.43%)   Blurred vision  1/70 (1.43%)   Eye disorders - Other, specify  2/70 (2.86%)   Abdominal Pain  5/70 (7.14%)   Colitis  1/70 (1.43%)   Diarrhea  2/70 (2.86%)   Nausea  2/70 (2.86%)   Death NOS  1/70 (1.43%)   Edema limbs  1/70 (1.43%)   Fatigue  3/70 (4.29%)